Business
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second QuarterBRAINTREE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is providing this reminder that data from the Company’s ACCESS-PVI trial will be presented by Francois Cornelis, MD, PhD, FCIRSE, Memorial Sloan Kettering Cancer Center, Department of Radiology. This is the first ti
About this update from Microbot Medical Inc.
[{"type":"image","alt":"Microbot Medical Inc.","displaySize":"","headline":null,"caption":"Microbot Medical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":225,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/aa6fc46ca058a537718c34f5b3ddfe4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l7bo53ve7EJ4Wyh46wBAyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/aa6fc46ca058a537718c34f5b3ddfe4e","width":225,"height":87}},"lazy":false},{"type":"text","content":"Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter","length":128,"tagName":"p"},{"type":"text","content":"BRAINTREE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is providing this reminder that data from the Company’s ACCESS-PVI trial will be presented by Francois Cornelis, MD, PhD, FCIRSE, Memorial Sloan Kettering Cancer Center, Department of Radiology. This is the first time data from the study will be presented via a podium presentation, to take place on Wednesday, April 2, 11:33am CT.","length":488,"tagName":"p"},{"type":"text","content":"ACCESS-PVI trial, a prospective, multicenter, single-arm trial evaluating the performance and safety of LIBERTY® in patients undergoing peripheral vascular interventions.","length":170,"tagName":"p"},{"type":"text","content":"In conjunction with the data presentation, members of the Company’s executive and clinical teams have been meeting with SIR attendees. The Company reaffirms that it expects the FDA’s decision with respect to 510(K) clearance of LIBERTY® during the current second quarter.","length":271,"tagName":"p"},{"type":"text","content":"About Microbot Medical®Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.","length":393,"tagName":"p"},{"type":"text","content":"Further information about Microbot Medical® is available at http://www.microbotmedical.com.","length":91,"tag...